Syngeneic Model for Preclinical Evaluation of Ovarian Cancer

Ovarian cancer is considered a relatively rare gynecologic malignancy but has one of the highest mortality rates due to the non-specific symptoms that occur in early stage disease. This results in most women being diagnosed with advanced stage disease. The incidence of ovarian cancer within the United States is approximately 22,000 cases per year and […]

Subcutaneous and Systemic Preclinical Modeling of A20 Murine B Cell Lymphoma

Lymphomas represent a set of lymphoid cell malignancies that can range from indolent to aggressive. B cell-derived lymphomas, specifically non-Hodgkin lymphoma (NHL), are the most prevalent, but this disease can also originate from T cells. In 2018, an estimated 74,680 new cases of NHL in the United States will be diagnosed, and 19,910 patient deaths […]

Hepa 1-6: A Murine Model of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is an aggressive malignancy which has gradually increased in incidence to affect one million people worldwide and is currently the third leading cause of cancer related deaths in the world.[1,2] The prevalence of HCC is highest in Asia and Africa due to high endemicity of hepatitis B and C viruses which strongly […]

HCC70: A Model of Triple Negative Breast Cancer

Table 1: Endpoint Analysis Following Treatment with Paclitaxel and Focal Radiation Group # Treatment Related Weight Change Median % ΔT/ΔC (day 63) % Regression (day 63) % Complete Regression % Partial Regression % Tumor Free Survivors Vehicle 4.8 100 0 0 0 0 Paclitaxel 4.4 72.2 0 0 0 0 […]

E0771 Syngeneic Breast Cancer Model

Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer lacking estrogen receptor, progesterone receptor, and HER2 amplifications; making it difficult to target therapeutically. Consequently, there’s a constant demand for better treatment options for TNBC. To help address the need for TNBC models, we highlighted the EMT6 model last month and […]

EMT-6 Syngeneic Breast Tumor Model – A Powerful Tool for Immuno-Oncology Studies

Breast cancer is the most common cancer among women in the United States and is the fourth leading cause of cancer death. In 2017, an estimated 252,710 new cases were diagnosed (15% of all new cancers) and 40,610 patient deaths occurred. Early detection initiatives together with improved treatment options have resulted in increases in the […]

ID8 Syngeneic Ovarian Cancer Model Response to Checkpoint Inhibitors

Fig. 2: Intraperitoneal ID8-luc: Representative BLI Images Over Time   Body Weight Changes with Use of Checkpoint Inhibitors Treatment with checkpoint inhibitors was not associated with any significant body weight change relative to control animals (Figure 3A). The median survival of animals treated with anti-mCTLA-4 was comparable to control animals […]

Models for Non-Small Cell Lung Carcinoma – Part 2

NCI-H1703 NCI-H1703 was derived from a stage 1 lung squamous cell carcinoma of a 54-year-old Caucasian male smoker. This cell line is of interest to the research community based on the high levels of platelet-derived growth factor receptor α (PDGFRα) amplification. NCI-H1703 is one of very few NSCLC models that […]

Models for Non-Small Cell Lung Carcinoma

Table 1:  Non-small Cell Lung Cancer Lines Available at MI Bioresearch Lung [NSCLC] A549 A549-Luc-C8 Calu-1 Calu-3 HCC827 HCC827-Luc-mCh-Puro NCI-H125 NCI-H125-Luc NCI-H1299 NCI-H1299-p53-V138-BP100-Luc NCI-H1650 NCI-H1703 NCI-H1703-Luc-mCh-Puro NCI-H1975 NCI-H1975-Luc NCI-H2110 NCI-H23 NCI-H292 NCI-H3122 NCI-H441 NCI-H460 NCI-H460-Luc2 NCI-H522 PC-9 Human

ID8: A Syngeneic Mouse Model for Testing Ovarian Cancer Immunotherapies

Ovarian cancer is an unmet medical need and particularly lethal because it is often detected only when disease is quite advanced. In 2017, approximately 22,440 women will be diagnosed with ovarian cancer in the United States, and approximately 14,080 deaths will occur. Combination platinum and anti-mitotic taxane based chemotherapy is the standard of care in […]

A20: Modeling B Cell Lymphoma in Mice

Lymphomas represent a highly heterogenous set of lymphoid cell malignancies. They can originate from either B or T cells, but B cell-derived lymphomas, specifically non-Hodgkin lymphoma (NHL), are the most prevalent. Lymphomas can be diagnosed in children and adolescents, but incidence of lymphoma increases significantly with age, the median age of diagnosis being 67 years. […]

Models for Pancreatic Cancer

PANC-1 PANC-1 was isolated from a 56-year-old Caucasian man with pancreatic ductal adenocarcinoma. Subcutaneous tumor growth is reliable and consistent, with tumor volume doubling every 5 days and typically reaching evaluation size (~750mm3) in approximately 29 days post implant. Treatment with gemcitabine (160mg/kg) is well tolerated and produces statistically significant […]

Focal Radiation in the Murine 4T1-luc2 Mammary Cancer Model

The use of immuno-oncology therapies have seen remarkable progress in the last five years and are currently undergoing clinical trial use in combination with a variety of agents including radiation therapy (RT).1 RT is a main-stay in clinical oncology treatments with approximately 60 percent of cancer patients receiving RT at some point during their care. […]

Pan02 – Pancreatic Ductal Adenocarcinoma Model Characterized for Immuno-oncology Applications

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer representing about 95% of all cases. In 2017, approximately 50,987 people will be diagnosed with PDAC in the United States, and approximately 40,936 patient deaths will occur, making PDAC one of the most lethal forms of cancer. Combination anti-metabolite and anti-mitotic taxane based […]

MM.1S: A Model for Multiple Myeloma

Mean Total Tumor Burden BLI Signal In SCID beige mice, the median tumor volume doubling time is ~2 days (Figure 3), and median time to morbidity/mortality endpoint is 35-45 days. To further optimize the MM.1S-pMMP-LucNeo model, we characterized growth in the NSG mouse strain which shows more aggressive disease onset […]

C1498: A Murine Model for Acute Myelogenous Leukemia (AML)

Survival (morbidity/mortality) kinetics (Figure 2A) show a median survival of approximately 23 days; although, the mice show no body weight loss during the course of disease progression (Figure 2B). Survival Kinetics and Body Weight Change Fig. 2: Survival kinetics (A) and body weight change (B) of C57BL/6 mice with disseminated […]

Colo-205 as a Translational Imaging Model for Colorectal Cancer

As mentioned in our HT-29 Model Spotlight last October, colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States for men and women combined. The death rate from CRC has been declining over the past several decades and there are now more than one million CRC survivors in the United […]

GL261-luc: A Model for Immunotherapy and Radiation Therapy

In addition to bioluminescence, MI has a host of other imaging technologies, including PET, MRI, SPECT, CT, and fluorescence modalities, to further interrogate parameters related to GBM such as tumor volume, vascular perfusion/permeability, metabolic activity, and edema. MI also has comprehensive In Vitro Services including flow cytometry to best evaluate […]

PC-3M-Luc-C6 – A Model for Prostate Carcinoma

Orthotopic Modeling In an effort to address this unmet need, MI Bioresearch has developed an orthotopic and a metastatic prostate model, PC-3M-Luc-C6. This cell line has been transfected with luciferase, which allows for disease and response monitoring through bioluminescence imaging (BLI). The orthotopic model is implanted directly into the prostate […]

4T1-luc2: An Orthotopic Mammary Cancer Model to Support Novel Immuno-Oncology Drug Discovery

Breast cancer is the second most deadly malignancy after lung cancer in woman in the United States, with an estimated 246,000 new cases and 40,450 deaths expected in 2016. Many treatment options for breast cancer exist including surgery, radiotherapy, anti-estrogen therapy, targeted therapies (e.g., trastuzumab), and chemotherapy. Despite these therapeutic advances, metastatic disease remains a […]

HT-29 as a Preclinical Model for Colorectal Cancer

In this model we have also evaluated the combination of radiation and gemcitabine (Figure 5) and illustrate the added benefit of the combination over either single agent treatment. Fig. 5: Subcutaneous Growth of HT-29 Following Combination Treatment with Localized Radiation and Gemcitabine Contact MI Bioresearch to discuss your next preclinical […]

786-O (pMMP-LucNeo) – A Model for Renal Cell Carcinoma

In an effort to address this unmet need, MI Bioresearch has developed an orthotopic RCC model, 786-O (pMMP-LucNeo) through implantation into the sub-renal capsule. This cell line has been transfected with luciferase, which allows for disease and response monitoring through bioluminescence imaging (BLI). In 786-O tumor bearing mice, we evaluated […]

5TGM1-luc – A Syngeneic Murine Model for Multiple Myeloma

The 5TGM1 multiple myeloma model arose spontaneously in aging C57BL/KaLwRij mice, and was propagated via serial passage in syngeneic mice prior to establishment of a cell line. MI Bioresearch’s 5TGM1 line has been luciferase-enabled to permit monitoring of growth in orthotopic sites such as the bone marrow by bioluminescent imaging […]